



REMARKS

Claims 1, 12, 13 and 14 have been amended and claim 4 has been canceled.

This amendment adds no new matter to the specification. Support for this amendment is found in the specification and claims as filed.

Attached hereto is a marked-up version of the changes made to the claims by the current amendment. The attached pages are captioned "Version with Markings to Show Changes Made".

No change of inventorship is necessitated by this amendment.

Applicants gratefully acknowledge the Examiner's indication of allowability of claim 35.

II. Discussion of the Rejection under 35 U.S.C. Sec. 103(a)

The rejection of claims 1, 4, 9-11, 14, 17, 21 and 25-28 under 35 U.S.C. Sec. 103 (a) as being unpatentable over JP 9-100283 in view of Teraji *et al.* (1986) or Teraji *et al.* (1981) has been maintained.

By this amendment, R¹ has been limited to a phosphono group in claim 1, and esters have been removed from claims 1, 12, 13 and 14. Applicants submit that the claims, as amended, are now commensurate with the unexpected results provided in the previously submitted Declaration.

By this amendment, claim 4 has been cancelled. Claims 9-11, 14, 17, 21 and 25-28 depend upon claim 1. Applicants submit that the amendments made to the independent claims renders the more specific dependent claims commensurate as well.

Therefore, Applicants respectfully request withdrawal of the Sec. 103(a) rejection.

C

III. Discussion of the Objection to Claims 7, 12, 13 and 29-34

The Examiner has indicated that claims 7, 12, 13 and 29-34 would be allowable if re-written in independent form including all of the limitations of the base claim and any intervening claims.

Claim 12 is an independent claim, from which claims 29-34 depend. By this amendment, claim 12 has been amended to delete the words "its ester". Therefore, Applicants submit that claim 12 and its dependent claims are now in condition for allowance.

Claims 7 and 13 depend upon claim 1. As claim 1 has been re-written to define R¹ as a phosphono group, Applicants submit that claims 7 and 13 are now in condition for allowance.

Therefore, Applicants respectfully request withdrawal of the objection to claims 7, 12, 13 and 29-34.

IV. Conclusion

Reconsideration of the claims as amended and allowance is requested. Should the Examiner believe that a conference with Applicants' attorney would advance prosecution of this application, the Examiner is respectfully requested to call Applicants' attorney at (847) 383-3391.

Respectfully submitted,

Dated: January 22, 2002

(847) 383-3391

(847) 383-3372

Elaine M. Ramesh

Elaine M. Ramesh, Ph.D., Reg. No. 43,032

Mark Chao, Ph.D., Reg. No. 37,293

Attorney for Applicants

Customer No. 23,115

Takeda Pharmaceuticals North America, Inc.
Intellectual Property Department
Suite 500, 475 Half Day Road
Lincolnshire, IL 60069 USA